Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

A six-year-old girl in China died after receiving an experimental gene-editing treatment for a rare neurodevelopmental disorder. The incident sparked scrutiny on ethics and safety of cutting-edge gene therapies, particularly when they involve children and individualized treatments.

The case, uncovered through a joint investigation by Science and Retraction Watch, sparked international concern as the child's death was never disclosed publicly, despite related preclinical research later being published in Nature.

What Happened?

According to the investigation, the six-year-old girl, identified by the pseudonym "Mei," had Snijders Blok-Campeau syndrome, a rare genetic condition. It caused symptoms like mild intellectual disability and developmental delays.

Her parents reportedly paid more than $800,000 to support development of a personalized ("n=1") gene-editing therapy designed specifically for their daughter's mutation.

In March 2025, she received a spinal infusion containing trillions of adeno-associated viruses (AAVs) carrying a CRISPR-based gene editor intended to correct the faulty gene in brain cells. Within days, she developed a severe immune reaction and died approximately one week after treatment.

An internal hospital review concluded that the most likely cause of death was an overwhelming immune response triggered by the viral delivery system rather than the gene-editing mechanism itself.

The controversy extends well beyond the patient's death. According to Science investigation:

• The child's death was not publicly disclosed.
• The child's treatment was omitted from a later Nature publication describing related preclinical work.
• Animal studies had reportedly shown warning signs, including severe liver and kidney toxicity at high doses.
• The girl's parents may not have been fully informed about the potential side effects of the therapy.

Following the investigation, local Chinese health authorities reportedly fined the hospital involved for faulty execution of the clinical research. Several experts have called for an independent review of the published research and greater transparency around experimental human gene-editing trials.

Also read: Ebola Outbreak in DR Congo Nears 3,000 Cases, 1,300 Deaths as UN Warns Virus Is 'Spreading Like Wildfire'

Bioethicists and gene therapy researchers say the case underscores the need for complete transparency whenever experimental therapies are tested on humans.

Hank Greely, director of the Center for Law and the Biosciences at Stanford University, told Science that the trial "shouldn't have gone to trial".

Pediatrician Marcelo Bellusci, who participates in gene therapy trials, told El País, "In this type of trial there can be serious side effects, but families are always informed about them. This team skipped the current rules."

About Gene-Editing Therapies

Gene-editing technologies such as CRISPR offer the possibility of correcting genetic mutations caused by diseases instead of simply treating symptoms. Several CRISPR-based therapies have shown remarkable success in inherited blood disorders, including sickle cell disease.

However, experts stress that therapies targeting the brain remain considerably more complex because they often require large viral doses and carry greater risks of immune complications.

As more individualized gene-editing therapies move toward human testing, experts argue that every serious adverse event must be reported promptly to regulators, journals, clinicians, and patients to ensure future treatments become both safer and more trustworthy.

Mongolia recently confirmed a suspected case of bubonic plague after a bacteriological laboratory delivered positive results. The National Center for Zoonotic Diseases confirmed on Friday that the case belongs to Mongolia's western Khovd province.

Mongolia Confirms First Human Case Of Bubonic Plague

According to reports, the patient contracted the infection after eating marmot meat during a visit to Ulaankhus soum in neighbouring Bayan-Ulgii province.

Mongolia's first confirmed case of bubonic plague has prompted officials to issue warnings against hunting and eating marmots, a known source of the deadly disease which is also considered a delicacy in the country.

The warnings also stated that individuals must avoid all forms of contact with the rodent, including handling their meat or internal organs. It also said avoid contact with sick or dead rodents as it could significantly increase the risk of infection.

The National Center for Zoonotic Diseases says 17 of Mongolia's 21 provinces are considered high risk regions for plague as the bacterium persists in wildlife.

Also read: What Was The Pseudo-Tuberculosis Like 'Syndrome K' Saved Thousand Lives During World War II?

Why Bubonic Plague Still Lurks In Mongolia?

The Black Death devastated Europe in the 14th century. Even today, a few countries still see cases of plague from time to time.

Humans typically get infected through flea bites from infected rodents, handling and close contact with infected animals and eating undercooked or raw marmot meat, which has been linked to several cases in Mongolia.

Mongolia has reported human plague cases to the World Health Organization since the 1980s. Sporadic infections continue to occur almost every year, particularly in the country's western and northern provinces.

The disease still lives centuries after it was eradicated because it is entrenched in wildlife rather than spreading continuously between people.

Humans are usually infected after being bitten by infected fleas or through hunting, skinning, or eating infected marmots.

Studies show that nearly 60% of Mongolia's reported plague cases since 1998 have been linked to close contact with infected marmots, highlighting why authorities repeatedly warn against hunting and consuming the animals.

Also read: How To Get Rid Of Fleas In Your House And Stop Them From Infecting Your Pets

Several infamous incidents related to the disease have sparked headlines in the last few years.

In 2019, a married couple died after eating raw marmot meat.

In 2020, a teenager also died after eating marmot meat, prompting temporary travel restrictions and heightened surveillance.

The latest confirmed human case in July 2026 follows the same familiar pattern.

Mongolia's challenge is not a new outbreak but an enduring zoonotic disease that resurfaces whenever humans come into contact with infected wildlife.

Where Else Does The Plague Still Exist?

Plague remains endemic in several parts of the world. According to the World Health Organization, the Democratic Republic of Congo, Madagascar, and Peru report the highest number of human cases globally. Since the 1990s, most reported cases have occurred in Africa.

Madagascar experiences seasonal plague almost every year, typically between September and April. The country drew international attention during a major 2017 outbreak, which caused more than 2,500 suspected, probable, and confirmed cases and over 200 deaths.

In the United States, plague is rare but has never disappeared. An average of about seven human cases are reported annually, mostly in rural parts of New Mexico, Arizona, Colorado, California, Oregon, and Nevada.

In 2026, Arizona reported its first human plague case in Apache County in more than a decade.

China has also reported occasional isolated human infections, particularly in Inner Mongolia.

The Ebola outbreak in the Democratic Republic of Congo (DRC) is expanding at an alarming pace, with confirmed infections nearing 3,000 and deaths exceeding 1,300, prompting the United Nations to warn that the virus is "spreading like wildfire" across eastern parts of the country.

The outbreak, caused by the rare Bundibugyo ebolavirus, has become the fastest-growing Ebola epidemic. Unlike Zaire strain, there are currently no approved vaccines or treatments specifically for Bundibugyo Ebola, making containment and management more challenging.

UN Says DRC Outbreak Is Spreading "Like Wildfire"

UN humanitarian officials have described the outbreak as one of the most severe public health emergencies. "The outbreak is spreading like wildfire," UN officials warned recently, highlighting that conflict, population displacement and attacks on healthcare facilities are preventing rapid containment efforts.

The World Health Organization (WHO) has repeatedly warned that the outbreak is becoming increasingly difficult to control.

According to WHO, a bunch of new infections cannot be linked to known transmission chains, indicating that the virus is spreading silently within communities.

Contact tracing remains inadequate to interrupt transmission, while insecurity and misinformation continue to hamper response efforts.

Also read: Ebola Scare In The UK After Humanitarian Worker Monitored In London Hospital; Here's what Happened

Health workers have also demonstrated strikes in some areas over unpaid dues, further disrupting patient care and containment efforts.

WHO has stressed that the global public health risk remains low, as Ebola spreads only through direct contact with the bodily fluids of infected individuals. However, the regional risk remains high because of active movement across borders.

Armed conflict in eastern DRC has limited access to affected communities, while attacks on health facilities, shortages of medical supplies, delayed laboratory testing and public distrust have slowed efforts to isolate patients, trace contacts, and contain the outbreak.

Hope Emerges As First Human Receives Experimental Bundibugyo Ebola Vaccine

Also read: Ebola Outbreak In Congo: UN Warns Frontline Responders As Cases Surface In New Areas

Amid the worsening outbreak, researchers have reached an important scientific milestone in vaccination. The first human volunteer has received an experimental vaccine targeting the Bundibugyo strain of Ebola, marking the world's first Phase I clinical trial.

The study, led by the University of Oxford, will evaluate the vaccine's safety by studying its ability to trigger an immune response in 50 healthy adults.

The vaccine, known as ChAdOx1 BDBV, uses the same viral vector platform that was employed for the Oxford-AstraZeneca COVID-19 vaccine. Professor Katrina Pollock, chief investigator at the Oxford Vaccine Group, described the launch as "an important milestone" in the effort to develop protection against a virus for which no licensed vaccine currently exists.

Africa CDC Director-General Dr Jean Kaseya also welcomed the development, noting that although early-stage trials will not immediately help affected communities battle the current outbreak, they are critical for building better tools against future epidemics.

WHO notes that currently approved Ebola vaccines, including Ervebo, are designed to protect against the Zaire ebolavirus, not the Bundibugyo strain responsible for the ongoing outbreak. Researchers are also in the process to determine whether existing vaccines may offer partial cross-protection while Bundibugyo-specific vaccines continue to be developed.

Alongside vaccine research, WHO and international partners have launched clinical trials in the DRC to evaluate experimental therapies, including the monoclonal antibody MBP134 and antiviral drug remdesivir, in patients infected with the Bundibugyo virus. Researchers hope these studies will identify effective treatment options for future outbreaks.